Previous Article | Next Article 
Molecular and Cellular Biology, July 1999, p. 4719-4728, Vol. 19, No. 7
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Transcriptional Cofactor CA150 Regulates RNA
Polymerase II Elongation in a TATA-Box-Dependent Manner
Carlos
Suñé1 and
Mariano A.
Garcia-Blanco1,2,3,*
Departments of Pharmacology and Cancer
Biology,1
Microbiology,2 and
Medicine,3 Levine Science Research
Center, Duke University Medical Center, Durham, North Carolina 27710
Received 5 March 1999/Returned for modification 5 April
1999/Accepted 9 April 1999
 |
ABSTRACT |
Tat protein strongly activates transcription from the human
immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) by
enhancing the elongation efficiency of RNA polymerase II complexes. Tat-mediated transcriptional activation requires cellular cofactors and
specific cis-acting elements within the HIV-1 promoter,
among them a functional TATA box. Here, we have investigated the
mechanism by which one of these cofactors, termed CA150, regulates
HIV-1 transcription in vivo. We present a series of functional assays that demonstrate that the regulation of the HIV-1 LTR by CA150 has the
same functional requirements as the activation by Tat. We found that
CA150 affects elongation of transcription complexes assembled on the
HIV-1 promoter in a TATA-box-dependent manner. We discuss the data in
terms of the involvement of CA150 in the regulation of Tat-activated
HIV-1 gene expression. In addition, we also provide evidence suggesting
a role for CA150 in the regulation of cellular transcriptional processes.
 |
INTRODUCTION |
Regulation of RNA polymerase II
(RNAP II) transcription initiation is accomplished by the involvement
of at least three different types of factors. General transcription
factors (GTFs) assemble near the start site of transcription and direct
the basal level of promoter expression. For example, the TATA-binding
protein (TBP) initiates assembly of transcription complexes by binding to the TATA box sequence in TATA-containing, class II gene promoters. A
second class of factors are either activators or repressors of
transcription which normally bind to specific DNA sequences and
regulate the rate of RNAP II transcription initiation. Finally, there
are adapter proteins (also called cofactors or mediators), which
provide a link between DNA-bound transcription factors and the GTFs and
can positively or negatively regulate transcription (20,
62). The joint action of GTFs, activators and/or repressors, and
adapters allows efficient initiation of transcription and subsequent
elongation by RNAP II complexes. Transcription elongation is also a
target for gene regulation, and many factors that stimulate elongation
and read-through have been identified (54). The
establishment of an elongation-competent transcription complex is a
process that probably involves phosphorylation of the C-terminal
heptapeptide repeat domain (CTD) of the largest subunit of RNAP II
(12), which consists of multiple repeats of the sequence YSPTSPS.
Genetic and biochemical approaches with yeast, and more recently with
mammals, have shown that RNAP II, GTFs, and adapters can be found in
preassembled complexes generically termed RNAP II holoenzyme
(38). The holoenzyme composition varies depending on the
protocol for purification, and there are indications that multiple
holoenzyme complexes may exist. Importantly, holoenzyme is responsive
to transcription activators (6, 26, 32), and recruitment of
holoenzyme to a promoter is sufficient for gene activation (1, 15,
17, 25).
The human immunodeficiency virus type 1 (HIV-1) long terminal repeat
(LTR) contains the elements of a prototypic class II eukaryotic
regulatory unit. It contains enhancer and promoter elements where
binding sites for many transcription factors have been identified
(24). The core HIV-1 promoter consists of a canonical TATA
box and two elements further downstream, which appear to be necessary
for transcriptional activity (63). Other relevant elements
include two and three tandem DNA-binding sites for the inducible
NF-
B and the ubiquitous Sp1 transcription factors, respectively.
Despite the presence of binding sites for multiple transcription
activators, transcription directed by the HIV-1 promoter is very weak
in vivo, and robust transcription requires the expression of the viral
transactivator Tat, which increases the level of transcription more
than 100-fold. Several studies have analyzed the contribution of
upstream elements to basal and activated HIV-1 transcription. In
particular, basal transcription is dependent more on NF-
B sites than
on Sp1 elements, whereas the opposite effect is seen for Tat-activated
transcription. TATA box sequences are required for Tat activation but
have a smaller contribution to basal activity from the HIV-1 promoter
(4, 29, 44).
Tat activates transcription by binding to an RNA structure called the
trans-activation response (TAR) element, a regulatory region
located at the 5' ends of all viral mRNAs (10). In the absence of Tat, the HIV-1 LTR produces mainly short, nonpolyadenylated transcripts, whereas in the presence of Tat, there is a substantial increase in the level of longer, polyadenylated transcripts. Tat affects the elongation efficiency of RNAP II complexes formed on the
HIV-1 promoter, and the mechanism of this regulation has been a matter
of intense investigation. Tat associates with a CTD kinase (21,
22), and the CTD of RNAP II is required for Tat trans
activation (9, 43, 61). These findings suggest that
phosphorylation of the RNAP II CTD can be increased by Tat. This is
particularly relevant because increasing CTD phosphorylation by a CTD
kinase has been shown to stimulate the elongation efficiency of RNAP II
(27). The identification of positive transcription elongation factor b (P-TEFb), as the protein complex that binds to Tat
and assembles onto the HIV-1 TAR element, has been a key step towards
our understanding of the mechanism of transcription activation of the
HIV-1 LTR by Tat (10). P-TEFb is comprised minimally of a
CTD kinase called CDK9, which is part of the Tat-associated kinase
(34, 60, 66), and its cyclin component, termed cyclin T1,
which binds directly to Tat (58). Immunodepletion of CDK9 inhibited basal and Tat-activated transcription in vitro (64, 66), and its overexpression abrogated Tat trans
activation in cells (19). Immunodepletion of cyclin T1
decreased basal and Tat activation in vitro (58).
Importantly, transfection of a human cyclin T1-expressing plasmid into
mouse cells, which are unable to respond to Tat via the HIV-1 TAR
element, rescued Tat transcriptional activation (58). Based
on these findings, it has been proposed that Tat recruits P-TEFb to the
HIV-1 TAR element, thus allowing the phosphorylation of the CTD and/or
other components of the transcription apparatus by CDK9 and increasing
the elongation competence of RNAP II complexes.
In addition to P-TEFb, other factors have been implicated in
Tat-mediated transcriptional activation. CA150 (coactivator of 150 kDa
[50]) and Tat-SF1 (Tat stimulatory factor 1 [65]) are nuclear proteins which were purified by
using in vitro transcription systems and Tat affinity chromatography.
Depletion of these proteins from HeLa nuclear extracts specifically
decreased Tat trans activation, and transient-transfection
experiments with either protein carried out in HeLa cells resulted in
alterations in the Tat-activated response. The fact that CA150 and
Tat-SF1 were isolated by Tat affinity chromatography, while no direct
binding between these factors and Tat has been reported, suggests that
CA150 and Tat-SF1 affect Tat trans activation indirectly.
Very little is known about the contribution of CA150 and Tat-SF1 to
Tat-mediated transcription activation of the HIV-1 promoter. In this
study, we delineated the role of CA150 in the regulation of RNAP II
transcription by using HIV-1 and other TATA-box-containing promoters.
We have found a selective role of CA150 in transcription from certain
promoters and have shown that CA150 regulates HIV-1 LTR transcription
in a TATA-box-dependent fashion. In addition, we provide evidence demonstrating that CA150 regulates transcription from the HIV-1 LTR, at
least in part, by affecting the elongation efficiency of RNAP II
complexes. The relevance of these findings to the regulation of HIV-1
gene expression is discussed.
 |
MATERIALS AND METHODS |
Plasmids.
pEFBOST7CA150 expressed the full-length CA150
protein under the control of the polypeptide chain elongation factor
1
promoter (37). PCR was used to obtain two fragments
representing the 5' and 3' portions of the CA150 gene by using the
CA150 cDNA plasmid (50) as a template. Pfu
polymerase (Stratagene, La Jolla, Calif.) was used in this and
subsequent PCRs. The following oligonucleotides were used:
5'-GGGAGATCTTGATGGCCCAACAGCAGGCCTTGAGG-3'
(forward) with 5'-GCTTTAACAGGCTCATCTTC-3' (reverse)
and 5'-GGGGAGCCCAAAGAAGAGGAGATGACT-3' (forward) with
5'-GGGAGATCTGATGCCCCTATGGAAGAGTATTTA-3'
(reverse). Each PCR fragment contained an overlapping
BclI restriction site and BglII (underlined)
ends. BclI- and BglII-digested PCR fragments were
ligated together into BamHI-digested pEFBOST7HRH1
plasmid (42) to create pEFBOST7CA150. The expressed
CA150 protein contains the 11-amino-acid T7 epitope tag at its amino terminus.
The reporter constructs HIV-CAT (promoter sequences from bp
640 to
+82), CMV-IE-CAT (promoter sequences from bp
467 to +71), and RSV-CAT
(promoter sequences from bp
290 to +34) are the same plasmid
containing the HIV-1, the cytomegalovirus (CMV) major immediate-early
(IE), and the Rous sarcoma virus (RSV) promoter sequences,
respectively, linked to the chloramphenicol acetyltransferase (CAT)
gene, and they have been previously described (3, 11). SV40
(simian virus 40 early)-CAT is the pSV2CAT plasmid (promoter sequences
from bp
271 to +69), and it was kindly provided by Cristina
Hernández-Munain (Duke University). pcTat, expressing the
86-amino-acid Tat protein under the control of the CMV promoter, has
been previously described (33). HSV-TK-LUC contains the herpes simplex virus (HSV) thymidine kinase (TK) promoter (sequences from bp
107 to +57), and it was kindly provided by Antonio A. Postigo
(Washington University, St. Louis, Mo.). The minimal HIV-1 promoter
plasmids (NF/SP [wild type] and NF-R) and the HIV-CAT mutated vectors
where the TATA box has been changed (SV40-TATA and m-TATA) or deleted
(d-TATA) have been described elsewhere (4) and were kindly
provided by Kuan-Teh Jeang (National Institute of Allergy and
Infectious Diseases, Bethesda, Md.). The 5' deletion mutants of the
4 integrin promoter have been described previously (45,
47), and they were kindly provided by A. A. Postigo. To
express human TBP, we used pCGNTBP, which adds a hemagglutinin (HA)
epitope tag to the amino terminus of the expressed protein, and it was
kindly provided by William P. Tansey (Cold Spring Harbor Laboratory,
Cold Spring Harbor, N.Y.) (51).
Cell culture and transfections.
We used 293T cells, a line
of transformed human epithelial kidney cells into which the gene for
the SV40 T antigen has been introduced (13).
Transient-transfection experiments involving this cell line required a
careful titration and balance of the different promoters tested.
Transfections were carried out with at least two different preparations
of each plasmid DNA purified by using kits from Qiagen Inc. (Santa
Clarita, Calif.). 293T cells were grown in Dulbecco's modified Eagle
medium (Gibco/BRL, Grand Island, N.Y.) supplemented with 10% fetal
bovine serum (Hyclone, Logan, Utah) and penicillin-streptomycin to 100 U and 100 µg per ml, respectively (Gibco/BRL). Transfections were
performed in 35-mm-diameter plates (Becton Dickinson Labware, Franklin
Lakes, N.J.). Each well was seeded with 5 × 105 cells
approximately 20 h prior to transfection. Cells were grown to
approximately 50% confluence and were transfected with the amounts
indicated in the figure legends by using calcium phosphate. The
reporter vector HSV-TK-LUC (10 ng per well) was used as an internal
control for transfection, and yeast tRNA carrier (Sigma, St. Louis,
Mo.) was used to keep constant the total amount of nucleic acids. Cells
in each well were carefully rinsed with phosphate-buffered saline (PBS)
and replenished with fresh medium 16 h after transfection, and
they were collected approximately 40 h after transfection. Cells
were rinsed with PBS and then lysed by three cycles of freezing in dry
ice and ethanol and thawing at 37°C in a water bath. After centrifugation, the supernatant was used immediately or stored at
80°C for future use. The cell extracts were normalized on the basis
of protein concentration by using the Bradford method with bovine gamma
globulin as a standard (Bio-Rad Laboratories, Hercules, Calif.). CAT
assays were done by the diffusion method of Neumann and coworkers
(41). Typically, 100 µg of cell protein was used in each
CAT assay. Luciferase activity was measured at room temperature with a
fixed amount of protein of individual cell extracts, luciferase assay
reagents from Promega Corp. (Madison, Wis.), and a semiautomatic
luminometer (LUMAT LB 9507; EG&G Berthold/Wallac Inc., Gaithersburg,
Md.). Values from one representative experiment are shown throughout
the paper. Similar results were obtained in at least three independent
transfection experiments in which relative CAT activities varied less
than 20% between experiments.
Antibodies and Western blotting.
Antibodies against CA150
have been described previously (50). Antibodies against the
T7 and HA tags were purchased from Novagen (Madison, Wis.) and Berkeley
Antibody Co. (Richmond, Calif.), respectively, and used accordingly to
their specifications. TBP-specific serum was obtained from Upstate
Biotechnology (Lake Placid, N.Y.).
Analysis of protein expression was carried out with whole-cell lysates
from 293T cells. Briefly, cells were washed twice with
PBS, and the
cell pellets were incubated with cold radioimmunoprecipitation
assay
buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate,
0.1% sodium
dodecyl sulfate [SDS], 50 mM Tris [pH 7.5]) containing
phenylmethylsulfonyl fluoride at 50 µg/ml during 30 min with gentle
hand shaking in a water-ice bucket. After spinning at 10,000 ×
g for 10 min at 4°C, the lysate was removed to a clean tube
and
used for protein analysis. For Western blot analysis, proteins
were
separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE),
transferred to an Immobilon-P (Millipore Corp., Bedford, Mass.)
membrane, and then incubated with the specific antiserum. After
washing, the membrane was incubated with a peroxidase-conjugated
secondary antibody (Amersham, Arlington Heights, Ill.), and bound
antibodies were detected by enhanced chemiluminescence
(Amersham).
RNA purification and RT-PCR.
Total cellular RNA was isolated
from transfected 293T cells by the method of Chomczynski and Sacchi
(8). After isolation, RNA samples were treated with RQ1
DNase I (Promega Corp.) according to the manufacturer's specifications
and then phenol-chloroform extracted and precipitated. Reverse
transcription (RT) reaction mixtures contained 4 µg of total RNA, 100 mM KCl, and 18 µM specific primers. The primers used were
5'-AAGCTTTATTGAGGCTTAAGCAGT-3' and
5'-GAAAACGGGGGCGAAGAA-3'. These primers were used to
synthesize cDNAs of 82 and 542 nucleotides, respectively. RT annealing
reaction mixtures were placed in boiling water for 1 min, then placed
at 50°C for 20 min, and then placed on ice. RT extension reaction mixtures contained 250 mM Tris-HCl (pH 8.3), 375 mM KCl, 15 mM MgCl2, 10 mM dithiothreitol, 500 µM each deoxynucleoside
triphosphate, and 200 U of Moloney murine leukemia virus reverse
transcriptase (Gibco) and were incubated at 37°C for 1 h. One
microliter of the appropriate dilution of each RT reaction mixture was
amplified in a 50-µl PCR mixture containing 200 µM (each) dATP,
dGTP, and dTTP; 50 µM dCTP; 0.5 µl of [
-32P]dCTP
(3,000 Ci/mmol; ICN Biomedicals, Irvine, Calif.); 1 µM each primer;
and 2.5 U of cloned Pfu DNA polymerase (Stratagene) with the
manufacturer's reaction buffer. The primers used were 5'-GGGTCTCTCTGGTTAGAC-3' (forward) and the same
oligonucleotide used in the RT reactions to measure transcripts of 82 nucleotides (reverse). Amplification reaction conditions consisted of
an initial denaturation step at 94°C for 2 min followed by 20 cycles
of denaturation at 94°C for 15 s, annealing at 55°C for
30 s, and extension at 72°C for 1 min. The reaction was finished
by a final 10-min extension at 72°C. PCR products were resolved on
nondenaturing 8% acrylamide-bisacrylamide (30:1)-Tris-borate-EDTA
gels. Electrophoresis was at 7 V/cm for approximately 5 h,
followed by drying and exposure to Amersham Hyperfilm-MP. Analysis was
performed with a Molecular Dynamics (Sunnyvale, Calif.) PhosphorImager.
 |
RESULTS |
Overexpression of CA150 represses HIV-1 basal and Tat-activated
transcription in vivo.
Several laboratories have studied the role
of Tat cofactors in the regulation of Tat-mediated transcription
activation of the HIV-1 promoter. In those studies, an effect on Tat
trans activation was observed when Tat-SF1 or P-TEFb
components were depleted from nuclear extracts or overexpressed in
cells. In some of these studies, an alteration of the basal activity of
the promoter (i.e., that in the absence of Tat) has been reported
(58, 64, 65), thus suggesting that these factors may also be
important for maintaining the basal level of HIV-1 transcription and/or
are able to interact with basal factors. We previously reported the
inhibition of Tat-activated transcription upon depletion of CA150 from
nuclear extracts and by overexpression of a deletion mutant CA150
protein in cells (50). We sought to further analyze the
contribution of CA150 to HIV-1 gene regulation.
In an effort to overexpress CA150 protein, we performed
transient-transfection experiments with several human cell lines as
well as a number of different expression vectors (data not shown).
A
full-length CA150 protein was overexpressed in 293T cells by
using the
promoter of the human polypeptide chain elongation factor
1

gene
contained in the pEFBOS vector (
37) (Fig.
1A). This
expression vector directed the
synthesis of CA150 efficiently
in 293T cells; therefore, it was chosen
for further studies. pEFBOS
vector was modified (
42) to
include the T7 epitope tag upstream
of the cloned gene, which allows
the detection of the expressed
protein by using specific antibodies
against the tag. To investigate
the role of CA150 in HIV-1
transcription, we sought to analyze
the effect of the overexpression of
a full-length CA150 protein
on the activity of the HIV-1 promoter in
the absence and presence
of the viral Tat activator in 293T cells.
Cotransfection of an
HIV LTR CAT reporter plasmid with a Tat-expressing
construct activated
transcription of the HIV-1 promoter in a
dose-dependent manner.
We observed a marked decrease in the activities
of both basal
and Tat-activated transcription of the HIV-1 promoter
when CA150
protein was overexpressed in these cells (Fig.
1B).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 1.
Overexpression of CA150 inhibits basal and Tat-activated
transcription from the HIV-1 LTR. (A) Analysis of CA150 protein
expression. Cells were transfected with 1, 2, and 3 µg of vector
alone (pEFBOST7) (lanes 1 to 3) and the same amounts of the
CA150-expressing construct (pEFBOST7-CA150) (lanes 4 to 6). Whole-cell
lysates were prepared, and proteins were resolved by SDS-PAGE and
transferred to a membrane. Antibodies against the protein were used to
localize CA150. (B) Effect of CA150 overexpression on basal and
Tat-activated transcription from the HIV-1 promoter. The levels of CAT
activity in extracts from cells that were cotransfected with 0.1 µg
of HIV-1 LTR reporter vector and the indicated amounts of Tat in the
presence of 3 µg of vector alone or the CA150-expressing construct
were measured. Transfection and activity assays were done as described
in Materials and Methods.
|
|
Several possibilities can explain the repression of the activity of the
HIV-1 promoter observed upon overexpression of CA150.
CA150 could be a
general transcription repressor, or it could
affect the activity of the
HIV-1 promoter indirectly. For example,
the repression could be due to
the sequestering of an RNAP II
GTF (so-called squelching), or the
effect could be more specific
to the HIV-1 promoter (e.g., disruption
of the normal stoichiometry
of a specific complex formed at the
promoter).
Inhibition of transcription by overexpressed CA150 depends on
specific promoter sequences.
To study the effect of the
overexpression of CA150 on transcription carried out by RNAP II, we
performed similar transient-transfection experiments with several viral
TATA-box-containing promoters. Of five promoters tested (HIV-1, CMV IE,
early SV40, RSV, and HSV TK), only the HIV-1 promoter was specifically
repressed by CA150 (Table 1). These data
indicate that CA150 is not a general repressor of transcription and
suggest that the repression mediated by the overexpression of CA150 is
not due to the squelching of a GTF or disruption of a complex required
for general transcription. The fact that several of the constructs used
in these experiments differ only in the promoter elements (HIV-1, CMV
IE, or RSV [see Materials and Methods]) also suggests that the
observed repression by CA150 depends on specific promoter sequences.
We also found that the cellular

4 integrin promoter was greatly
repressed by CA150 (Fig.
2A). The protein
product of the

4 integrin gene is a member of the integrin family
that mediates
attachment of lymphoid and myeloid cells to extracellular
matrixes
and is also involved in cell-cell interactions. In addition to
the immune system,

4 integrin is also expressed in a developmentally
regulated pattern in skeletal muscle, where a role in its normal
development has been proposed (
48). Overexpression of CA150
repressed transcription from the TATA-box-containing

4 integrin
promoter in a dose-dependent manner (Fig.
2B). These results indicate
that overexpression of CA150 can interfere with transcription
carried
out by RNAP II from certain TATA-box-containing promoters.

View larger version (9K):
[in this window]
[in a new window]
|
FIG. 2.
Overexpression of CA150 inhibits the activity of the
4 integrin promoter. (A) The indicated amounts of the 4 integrin
reporter vector were cotransfected into 293T cells in the presence of 3 µg of vector alone or the CA150-expressing construct. (B) The same
cotransfection experiment was carried out with a fixed amount of 4
integrin reporter vector (1.6 µg) and the indicated concentrations of
the CA150-expressing plasmid. Empty vector was used to keep the total
amount of DNA constant. Transfection and activity assays were done as
described in Materials and Methods.
|
|
TATA box sequences are critical in the regulation of the HIV-1
promoter by CA150.
To study which regions of the HIV-1 promoter
are important for repression by overexpressed CA150, we performed
transient-transfection experiments with a series of 5' promoter
deletion constructs. We used a set of HIV-1 constructs that were
originally described by Berkhout and Jeang (4). NF/SP (wild
type) contains a minimal HIV-1 promoter with Sp1 and NF-
B sites (up
to bp
105). The basal activity of this promoter was similar to the
activity of the HIV-1 promoter containing complete enhancer sequences
(up to bp
640) (Fig. 3A). We carried
out cotransfection experiments with either the HIV-1 construct
containing complete enhancer sequences (HIV-CAT) or the deletion mutant
construct (NF/SP) and the CA150-expressing vector. We observed an
inhibition of promoter activity with both HIV-1 constructs, which
indicates that most of the HIV-1 LTR is dispensable for CA150-dependent
inhibition (Fig. 3A). We noticed a reproducible lower level of
repression with the NF/SP (wild-type) construct, which could indicate
an effect of upstream sequences in CA150 inhibition (see below).
Further deletion of the NF-
B and Sp1 sites produced a minimal
promoter with an almost undetectable level of basal activity in 293T
cells (data not shown).

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 3.
Repression mediated by overexpression of CA150 requires
specific promoter sequences. (A) Effect of CA150 overexpression on the
activity of HIV-1 LTR constructs: CA150 overexpression inhibits HIV-1
promoter activity in a TATA-box-dependent manner. A schematic
representation of the HIV-1 promoter constructs is shown. Numbers on
the constructs indicate the amount of viral sequences present. NF-R has
both NF- B sites in a reverse orientation (arrow on top). The
indicated HIV-1 LTR constructs (0.1 µg) were cotransfected into 293T
cells in the presence of 3 µg of vector alone ( CA150) or
CA150-expressing vector (+CA150). Numbers indicate CAT activity from
transfected-cell extracts (see Materials and Methods). The
transcription activity from HIV-CAT, NF/SP (wild-type), and NF-R
constructs was repressed by overexpressing CA150. Changing the TATA box
sequence to TATTTAT (SV40-TATA) or to the random sequence
GTCAC (m-TATA) or using a construct where the TATA box was deleted
(d-TATA) abrogated the repression mediated by overexpression of CA150.
The abilities of these constructs to respond to Tat are shown in the
last column. 293T cells were cotransfected with 0.1 µg of the
indicated HIV-1 reporter constructs, 25 ng of pcTat, and 10 ng of
HSV-TK-LUC expression plasmid. The level of Tat activation of NF/SP
(wild-type) plasmid was set at 100. (B) Effect of CA150 overexpression
on the activity of the 4 integrin promoter. A schematic
representation of the 5' 4 integrin reporter constructs is shown.
Numbers in the construct name indicate the amount of 5' flanking region
present. The 5' 4 integrin reporter constructs were cotransfected
into 293T cells in the presence of 3 µg of vector alone or the
CA150-expressing construct. The approximately threefold reduction in
transcription activity of the constructs containing sequences upstream
to bp +600 has been described previously (45). Transfection
and activity assays were done as described in Materials and Methods.
|
|
To determine whether the altered activity of the HIV-1 promoter upon
CA150 overexpression was mediated by the TATA box, we
performed
cotransfection experiments with the rest of the constructs
shown in
Fig.
3A. The NF-R construct has both NF-

B elements in
a reverse
orientation, and its activity was approximately one-third
of that of
HIV-CAT or NF/SP (wild type), in agreement with the
results of Berkhout
and Jeang (
4) (Fig.
3A). As shown with
HIV-1 constructs with
enhancer sequences, transient cotransfection
of this construct with
CA150 showed a marked decrease of its activity
(Fig.
3A). We next
tested HIV-1 CAT reporter constructs with the
TATA element replaced by
TATTTAT (SV40-TATA), replaced by the
random sequence GTCAC
(m-TATA), or deleted (d-TATA). Previous
work with these TATA mutant
constructs showed that the transcription
start site was shifted by only
a few bases (
4). The basal activities
of these mutant HIV-1
promoters were one-third of the activity
of the wild-type construct and
similar to the activity of the
NF-R vector (Fig.
3A). Strikingly, the
transcription activities
of these three mutant constructs were not
repressed by CA150 in
cotransfection experiments (Fig.
3A). These
results indicated
that the HIV-1 TATA box is important in the
transcription repression
of the HIV-1 promoter mediated by
overexpression of CA150. The
quantitative difference observed with the
NF/SP construct is consistent
with a necessary, although possibly not
sufficient, role for the
HIV-1 TATA box element in the repression
mediated by overexpression
of
CA150.
We also sought to analyze transcription activity of the mutant HIV-1
constructs in the presence of Tat. As shown in Fig.
3A,
those
constructs with a wild-type TATA box (HIV-CAT, NF/SP [wild
type], and
NF-R) were strongly activated by Tat. Replacement of
the TATA element
with the SV40 TATA box (SV40-TATA) produced a
construct that was
fourfold less activated by Tat. Changing the
TATA box to the random
sequence GTCAC (m-TATA) or deleting the
TATA box (d-TATA) produced
constructs that lost the ability to
respond to Tat (Fig.
3A). Our
results confirm previous studies
using these constructs (
4)
and strengthen the importance of
the HIV-1 TATA box in Tat-mediated
transcriptional activation.
Interestingly, HIV-1 constructs which are
fully responsive to
Tat were also repressed by overexpressed CA150, and
HIV-1 constructs
which are nonresponsive to Tat were also unaffected by
overexpressed
CA150 (Fig.
3A). Therefore, it appears that
CA150-mediated repression
and Tat
trans activation have the
same promoter structure requirement,
which is critically dependent on
the TATA box. This also may indicate
that Tat and CA150 are capable of
modifying the same RNAP II transcription
complexes assembled on the
HIV-1 TATA
box.
We have shown above that transcription from the

4 integrin promoter
was also repressed by overexpression of CA150 (Fig.
2).
In order to
dissect the promoter elements necessary for repression
by CA150
overexpression, we used a series of 5' deletions of the

4 integrin
promoter (Fig.
3B). Previous experiments utilizing
these constructs
demonstrated the presence of two sites for the
zinc finger/homeodomain
ZEB protein at bp

361 and

399 that diminished
the activity of the

4 integrin promoter in a variety of cell
lines tested
(
45). We also found an approximately threefold
reduction in
promoter activity when the constructs containing
those sites were used
in 293T cells (Fig.
3B,

600,

1.2, and

2.0

4CAT constructs).
Transient-cotransfection experiments using
the

4 5' deletion
constructs and CA150 expression vector indicated
that CA150 repression
was mediated by the core promoter sequences,
consisting of only a
canonical TATA box sequence (

42

4CAT in
Fig.
3B). This finding
ruled out the requirement for upstream
promoter elements in the
mechanism of CA150 repression and indicated
that sequences downstream
of position

42 are required for the
inhibition by CA150 on the

4
integrin
promoter.
Overexpression of TBP can alleviate CA150-mediated transcription
repression.
Overexpression of CA150 did not cause a general
repression of all RNAP II transcription but instead was restricted to
certain types of promoters, including the HIV LTR and
4 integrin
promoter (Table 1 and Fig. 2). These results suggest that the mechanism by which the overexpression of CA150 represses transcription is not due
to generalized sequestration of TBP, thereby inhibiting efficient
transcription initiation. The fact that changes in TATA box sequences
disrupted the repression observed in HIV-1 transcription (Fig. 3A),
however, was suggestive of a role of TBP in the mechanism of CA150
action. For example, CA150 could be affecting specific TBP-containing
complexes. Thus, we sought to investigate the effect of the
overexpression of TBP on the repression of the HIV-1 promoter mediated
by CA150. We used the mammalian expression vector pCGNTBP (51), which adds a 15-amino-acid HA epitope tag to the amino terminus of the expressed TBP (Fig. 4A).
Cotransfection of pCGNTBP with the
HIV-CAT reporter vector did not significantly change (1.2-fold
increase) the basal activity of the HIV-1 promoter under these
conditions (Fig. 4B). Overexpression of TBP relieved repression by
CA150 (Fig. 4B) (10-fold versus 2-fold repression in the absence or
presence of overexpressed TBP, respectively). This was not due to a
reduction in expression of the CA150 protein, as CA150 expression was
not decreased as analyzed by Western blotting with T7 tag-specific
antibodies (Fig. 4C). HA-specific antibodies were used to analyze the
overexpressed TBP (Fig. 4C).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 4.
TBP can alleviate CA150-mediated repression of the HIV-1
promoter. (A) Analysis of TBP expression. Fifty micrograms of extracts
from 293T cells transfected with 1, 10, 50, 100, and 500 ng of pCGNTBP
(lanes 1 to 5) or mock transfected (lane 6) was subjected to SDS-PAGE
and Western blot analysis. Antibodies against TBP ( -TBP) and the HA
epitope tag ( -HA) were used to visualize the proteins. (B) HIV-CAT
reporter plasmid (0.1 µg) was cotransfected into 293T cells with 0.1 µg of pCGN (empty vector) ( TBP) or pCGNTBP (+TBP) in the presence
of 3 µg of vector alone (black bars) or CA150-expressing construct
(hatched bars). Transfection and activity assays were done as described
in Materials and Methods. (C) Analysis of CA150 and TBP protein expression in the transfected cells. Twenty
micrograms of transfected-cell extracts was used in SDS-PAGE and
Western blot analysis to analyze protein expression. Antibodies against
the T7 and HA epitope tags were used to visualize CA150 and TBP,
respectively.
|
|
Overexpression of CA150 decreases transcription elongation from the
HIV-1 promoter.
Our data above show a TATA box dependence for
CA150-mediated HIV-1 LTR repression (Fig. 3A). As mentioned, the TATA
box element is also essential for the specific stimulation of
transcription elongation of the HIV-1 LTR by Tat. Based on these
findings, together with data suggesting a role for CA150 in Tat
trans activation (50), we hypothesized a role for
CA150 in transcription elongation from the HIV-1 LTR. In order to test
this possibility, the effect of CA150 on transcription directed from
the HIV-1 LTR was further analyzed by quantifying the transcripts
synthesized in transfected 293T cells. A quantitative RT-PCR protocol
was designed to measure transcripts of different lengths derived from
the HIV-1 promoter (Fig. 5A). Two
specific oligonucleotides were used such that each one would serve to
synthesize cDNA fragments of 82 and 542 nucleotides, respectively, in
the RT reaction. Hence, this assay allowed us to measure the relative
amounts of transcription complexes that reached nucleotides +82 and
+542 of the nascent transcript.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
Overexpression of CA150 reduces transcriptional
elongation from the HIV-1 LTR. RNA from transfected 293T cells was
isolated and subjected to RT-PCR analysis. (A) Representation of the
RT-PCR assay used. A schematic map of the relevant regions in the
HIV-CAT reporter construct is shown. The start site of transcription
(+1) is indicated with an arrow. The relative positions of the specific
primers used in the RT reaction mixture are shown. These RT specific
primers measured transcription complexes that reached nucleotides +82
(Short) and +542 (Long) relative to the +1 start site of transcription.
For PCR, the RT reaction mixtures were subsequently amplified with the
same set of primers (F and Short) to compare directly the radioactive
signals (see Materials and Methods). (B) RT-PCR assay. PCR products
were linear over the range of concentrations used. RNA from cells
transfected with the control plasmid was isolated and reverse
transcribed in the presence (+RT) or absence ( RT) of reverse
transcriptase enzyme. One microliter of the RT reaction mixture and
subsequent fivefold dilutions were subjected to amplification by PCR
and visualized as described in Materials and Methods. Molecular size
markers (in base pairs) are indicated on the left. The position of the
labeled PCR product is also indicated. (C) Inhibition of HIV-1
transcriptional elongation by overexpressed CA150. RNA from cells
transfected with the control plasmid or CA150 expression construct
(CA150) was isolated and reverse transcribed by using the short and
long RT specific primers. RT reaction mixtures were subsequently
amplified by the PCR approach described for panel A. Molecular size
markers (in base pairs) are indicated on the left. The position of the
labeled PCR product is also indicated. Quantification was performed to
yield values for the radioactive signals from PCR products (see
Materials and Methods and Results).
|
|
RNA from transfected 293T cells was isolated and reverse transcribed
with these specific primers. RT reaction mixtures were
subsequently
amplified by PCR with the same set of primers to
compare directly the
radioactive signals (Fig.
5A) (see Materials
and Methods). The RT-PCR
assay was linear over the range of concentrations
used (Fig.
5B).
Figure
5C shows the results from a representative
experiment. The level
of +82 transcripts was affected less than
twofold, versus a fivefold
decrease in the level of +542 transcripts.
The same results were
obtained in RT-PCR analysis with samples
from a second independent
transfection experiment (data not shown).
Based on these results, we
conclude that the overexpression of
CA150 repressed transcription from
the HIV-1 LTR, at least in
part, by decreasing the level of
elongation-competent transcription
complexes.
 |
DISCUSSION |
It has recently been demonstrated that activation of the HIV-1
promoter by Tat requires the assembly of a functional Tat-P-TEFb complex on the TAR element (34, 58, 60, 66). The interaction between Tat and cyclin T1, one of the components of P-TEFb, has recently been investigated by two groups (5, 16). Less
information is available on the roles that other Tat cofactors play in
this process (28, 50, 65). CA150 was purified by using an in vitro transcription system and Tat affinity chromatography
(50). In vitro and in vivo experiments suggested that CA150
is necessary, although not sufficient, for Tat-mediated transcriptional
activation of the HIV-1 promoter (50). Here, we have used a
series of functional assays to further evaluate the role of CA150 in
HIV-1 transcription.
First, we demonstrated that overexpression of CA150 protein reduces the
activity of HIV-1 basal and Tat-activated transcription of the HIV-1
LTR. This inhibition is specific, since the activity of other promoters
remained unchanged (Table 1), arguing against depletion of a limiting
GTF (i.e., squelching). Next, we showed that the inhibition mediated by
CA150 overexpression depends on a specific TATA box sequence in the
HIV-1 promoter (Fig. 3A). It is clear from the work of several
laboratories that the assembly of Tat-responsive, elongation-competent
RNAP II transcription complexes depends critically on the TATA box
element within the HIV-1 LTR. The HIV-1 LTR also specifies a
TATA-box-independent transcription complex, which cannot be activated
by Tat (our data and references 4, 29, and
44). Therefore, the HIV-1 promoter can specify two
different types of transcription complexes, which respond differently
to Tat. In our experiments, changes in the HIV-1 TATA box sequence had
a minor effect on basal transcription (about one-third of the wild-type
activity) and caused a severe abrogation of Tat trans
activation. Our data also show that HIV-1 constructs able to be
strongly activated by Tat (HIV-CAT, NF/SP [wild type], and NF-R) were
also repressed by CA150 but that altered HIV-1 TATA box constructs
(SV40-TATA, m-TATA, and d-TATA) were neither activated by Tat nor
repressed by CA150 (Fig. 3A). These data indicate that CA150
overexpression affects the specific RNAP II complexes whose assembly
critically depends on the HIV-1 TATA box and which are also responsive
to Tat.
How does overexpression of CA150 inhibit HIV-1 transcription? In the
absence of overexpressed CA150, TBP nucleates the assembly of the
components of an active preinitiation complex (PIC), probably by
recruiting an RNAP II holoenzyme (46). The formation of this PIC is critically dependent on a functional (wild-type) HIV-1 TATA box
element. These transcription complexes are also Tat responsive; therefore, they can elongate efficiently. Transcription complexes formed on mutated HIV-1 TATA box elements may be devoid of critical components and therefore be affected by neither overexpressed CA150 nor
Tat. Overexpression of CA150 could alter the activity of the
Tat-responsive, TATA-dependent transcription complex, maybe by
sequestering one of its components which is necessary for efficient transcriptional elongation. This hypothesis is consistent with previously observed interactions between CA150 and components of RNAP
II holoenzyme complexes (50). More recently, we have detected an interaction between CA150 and proteins known to promote RNAP II transcriptional elongation, which supports this model further
(19a). According to this, overexpression of CA150 results in
the formation of TATA-box-dependent transcription complexes that are
unable to elongate efficiently. Indeed, our data show that
overexpressed CA150 can decrease the amount of transcripts derived from
the HIV-1 LTR and that this defect is at the elongation level (Fig. 5).
At present, it is not known whether CA150 affects the elongating RNAP
II complex directly or during the formation of an active,
elongation-competent PIC (e.g., by disrupting or sequestering the RNAP
II holoenzyme or critical components of this complex). Identification
and purification of CA150-binding factors within the transcription
complex will help us to understand how this protein exerts its
regulation and the mechanism underlying repression.
We have also shown that TBP overexpression may counteract CA150
inhibition of the HIV-1 LTR (Fig. 4B). As mentioned before, the
specific repression on transcription from certain types of promoters by
overexpressed CA150 (Table 1 and Fig. 2) suggested that repression was
not due to a direct effect on a limiting GTF. These data, together with
experiments showing no physical interaction between CA150 and TBP in
vitro (unpublished data), make it unlikely that this GTF is the direct
target of the repression. The mechanism by which TBP relieves the
inhibition mediated by overexpressed CA150 is unknown. Synergy between
Gal4-TBP and Tat has been reported recently (31, 59). Those
data may indicate that TBP increases the formation of Tat-responsive
transcription complexes whose assembly is dependent on a functional
(wild-type) HIV-1 TATA box element. In our experiments, overexpressed
TBP may counteract CA150 repression by increasing the formation of
these transcription complexes. To date, it is not clear if recruitment
of TBP activates the basal level of the HIV-1 promoter (31,
59). Clarification of this will be important to determine whether
the Tat-responsive RNAP II complexes are the target of CA150.
Our results agree with the notion that HIV-1 TATA box
sequences affect the elongation of transcripts initiated from the
HIV-1 LTR. Sequences within promoter regions have been shown to affect late events in transcription in other systems. For example, the efficiency with which RNAP terminates transcription at a given termination site can be modulated by sequences linked to
prokaryotic promoters (52). In addition, promoter sequences
required for efficient elongation and premature termination have been
defined in the human c-myc gene (36).
The transcription repression mediated by CA150 on the HIV-1 promoter
has similarities to effects seen upon overexpression of the adenovirus
E1A gene product. Overexpression of E1A protein leads to an inhibition
of basal and Tat-activated transcription of the HIV-1 LTR in vivo
(53, 56, 57) and in vitro (49). E1A did not
affect the RSV promoter in vitro (49). Strikingly, E1A
repression of the HIV-1 promoter was dependent on a functional TATA box
sequence (53). Mutational analyses have identified the amino
terminus and the CR1 region of E1A protein to be important for its
repressive effect (49, 53, 56, 57). These mutations did not
disrupt the binding of E1A to TBP (which lies within the CR3 region in
E1A); thus, it is unlikely that TBP mediates the repression. The same
studies established a good correlation between repression and binding
of E1A to CBP-p300. CBP and p300 are nuclear proteins that participate
in a variety of transcription pathways and cell growth control
(14, 18). They interact with transcriptional activators as
well as repressors; therefore, it has been suggested that promoters
regulated by molecules requiring CBP-p300 would be repressed by E1A.
CBP-p300 associates with RNAP II holoenzyme and interacts with RNAP II
(7, 39, 40). E1A may disrupt interactions between
transcription factors and RNAP II that are mediated by CBP-p300.
Interestingly, CBP-p300 has been shown recently to interact with Tat
and regulate the activity of the HIV-1 promoter (2, 23, 35).
It will be of interest to test whether overexpression of CBP-p300 can
abrogate CA150-mediated repression of the HIV-1 promoter.
Another protein capable of repressing transcription from many viral and
cellular promoters whose initiation is dependent on the presence of a
TATA box is p53 (30). A proline-rich motif in p53 has been
shown to be essential for repression (55). Similarly, the
amino and CR1 regions of E1A protein, which are involved in its
repressive effects, likewise contain many prolines. These data may
explain the specific inhibition of Tat-activated, but not basal,
transcription from the HIV-1 promoter upon overexpression of a
truncated CA150 protein in HeLa cells (50). The truncated CA150 protein contained a deletion in the amino-terminal part which
included, among other motifs, the polyproline-rich region, which may be
important for repression of HIV-1 basal transcription activity. In
fact, we have found that deletion of the polyproline-rich region of
CA150 reduced CA150-mediated repression by 50% in 293T cells
(unpublished results). We cannot rule out, however, an effect of the
different cell lines used in these studies. Mutational studies are in
progress to elucidate the roles of different regions and motifs of
CA150 in the transcriptional repression by overexpression of this
protein. Together, these data implicate proline-rich regions in
transcription repression. Further investigation into the mechanism by
which these otherwise unrelated proteins inhibit transcription will
shed light on their specific roles in regulating gene expression.
Finally, the
4 integrin promoter is also repressed by CA150
overexpression (Fig. 2 and 3B). This finding suggests that CA150 regulates transcription of cellular genes. Nucleotide sequence analysis
of the HIV-1 and
4 integrin minimal promoters reveals similarities
only at the TATA box motif (TATAA and TATA for the HIV-1 and
4
integrin promoters, respectively). The other promoters used in this
study contained TATA box sequences that were more divergent from the
consensus (TATATAA, TATTTAT, TATTTAA,
and TATTAA for the CMV, early SV40, RSV, and
HSV-TK-LUC promoters, respectively). The overexpression of CA150 may
affect a specific subset of factors whose assembly requires certain
types of TATA box sequences. Whether the HIV-1 and
4 integrin
promoters are transcriptionally regulated through similar mechanisms
will be the focus of further investigation.
 |
ACKNOWLEDGMENTS |
We thank C. Hernández-Munain and members of the M. A. Garcia-Blanco laboratory for their help during the course of this work. We also thank P. Bohjanen, R. Carstens, A. Goldstrohm, C. Hernández-Munain, and Y. Liu for critical review of the
manuscript. We also thank K.-T. Jeang for HIV-1 promoter constructs, A. Postigo for
4 integrin promoter constructs, and W. Tansey for pCGNTBP.
This research was supported by a grant from the NIH to M.A.G.-B.
C.S. is supported by the NIAID Research Training Program in AIDS to the
Division of Infectious Diseases at Duke University Medical Center. We
also acknowledge the Keck Foundation for support to the Levine Science
Research Center.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pharmacology and Cancer Biology, Box 3686, Duke University Medical
Center, Durham, NC 27710. Phone: (919) 613-8632. Fax: (919) 613-8646. E-mail: garci001{at}mc.duke.edu.
 |
REFERENCES |
| 1.
|
Barberis, A.,
J. Pearlberg,
N. Simkovich,
S. Farrell,
P. Reinagel,
C. Bamdad,
G. Sigal, and M. Ptashne.
1995.
Contact with a component of the polymerase II holoenzyme suffices for gene activation.
Cell
81:359-368[Medline].
|
| 2.
|
Benkirane, M.,
R. F. Chun,
H. Xiao,
V. V. Ogryzko,
B. H. Howard,
Y. Nakatani, and K. T. Jeang.
1998.
Activation of integrated provirus requires histone acetyltransferase.
J. Biol. Chem.
273:24898-24905[Abstract/Free Full Text].
|
| 3.
|
Berger, J.,
J. Hauber,
R. Hauber,
R. Geiger, and B. R. Cullen.
1988.
Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells.
Gene
66:1-10[Medline].
|
| 4.
|
Berkhout, B., and K. T. Jeang.
1992.
Functional roles for the TATA promoter and enhancers in basal and Tat-induced expression of the human immunodeficiency virus type 1 long terminal repeat.
J. Virol.
66:139-149[Abstract/Free Full Text].
|
| 5.
|
Bieniasz, P. D.,
T. A. Grdina,
H. P. Bogerd, and B. R. Cullen.
1998.
Recruitment of a protein complex containing Tat and cyclin T1 governs the species specificity of HIV-1 Tat.
EMBO J.
17:7056-7065[Medline].
|
| 6.
|
Chao, D. M.,
E. L. Gadbois,
P. J. Murray,
S. F. Anderson,
M. S. Sonu,
J. D. Parvin, and R. A. Young.
1996.
A mammalian SRB protein associated with an RNA polymerase II holoenzyme.
Nature
380:82-85[Medline].
|
| 7.
|
Cho, H.,
G. Orphanides,
X. Sun,
X. J. Yang,
V. Ogryzko,
E. Lees,
Y. Nakatani, and D. Reinberg.
1998.
A human RNA polymerase II complex containing factors that modify chromatin structure.
Mol. Cell. Biol.
18:5355-5363[Abstract/Free Full Text].
|
| 8.
|
Chomczynski, P., and N. Sacchi.
1987.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:156-159[Medline].
|
| 9.
|
Chun, R. F., and K. T. Jeang.
1996.
Requirements for RNA polymerase II carboxyl-terminal domain for activated transcription of human retroviruses human T-cell lymphotropic virus 1 and HIV-1.
J. Biol. Chem.
271:27888-27894[Abstract/Free Full Text].
|
| 10.
|
Cullen, B. R.
1998.
HIV-1 auxiliary proteins: making connections in a dying cell.
Cell
93:685-692[Medline].
|
| 11.
|
Cullen, B. R.
1986.
Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism.
Cell
46:973-982[Medline].
|
| 12.
|
Dahmus, M.
1996.
Reversible phosphorylation of the C-terminal domain of RNA polymerase II.
J. Biol. Chem.
271:19009-19012[Free Full Text].
|
| 13.
|
Dubridge, R. B.,
P. Tang,
H. C. Hsia,
P. M. Leong,
J. H. Miller, and M. P. Calos.
1987.
Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system.
Mol. Cell. Biol.
7:379-387[Abstract/Free Full Text].
|
| 14.
|
Eckner, R.
1996.
p300 and CBP as transcriptional regulators and targets of oncogenic events.
Biol. Chem.
377:685-688.
|
| 15.
|
Farrell, S.,
N. Simkovich,
Y. Wu,
A. Barberis, and M. Ptashne.
1996.
Gene activation by recruitment of the RNA polymerase II holoenzyme.
Genes Dev.
10:2359-2367[Abstract/Free Full Text].
|
| 16.
|
Garber, M. E.,
W. Ping,
V. N. KewalRamani,
T. P. Mayall,
C. H. Herrmann,
A. P. Rice,
D. R. Littman, and K. A. Jones.
1998.
The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein.
Genes Dev.
12:3512-3527[Abstract/Free Full Text].
|
| 17.
|
Gaudreau, L.,
M. Adam, and M. Ptashne.
1998.
Activation of transcription in vitro by recruitment of the yeast RNA polymerase II holoenzyme.
Mol. Cell
1:913-916[Medline].
|
| 18.
|
Giles, R. H.,
D. J. M. Peters, and M. H. Breuning.
1998.
Conjunction dysfunction: CBP/p300 in human disease.
Trends Genet.
14:178-183[Medline].
|
| 19.
|
Gold, M. O.,
X. Yang,
C. H. Herrmann, and A. P. Rice.
1998.
PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo.
J. Virol.
72:4448-4453[Abstract/Free Full Text].
|
| 19a.
| Goldstrohm, A., C. Suñé, and M. A. Garcia-Blanco. Unpublished data.
|
| 20.
|
Hampsey, M.
1998.
Molecular genetics of the RNA polymerase II general transcriptional machinery.
Microbiol. Mol. Biol. Rev.
62:465-503[Abstract/Free Full Text].
|
| 21.
|
Herrmann, C. H., and A. P. Rice.
1995.
Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor.
J. Virol.
69:1612-1620[Abstract].
|
| 22.
|
Herrmann, C. H., and A. P. Rice.
1993.
Specific interaction of the human immunodeficiency virus Tat proteins with a cellular protein kinase.
Virology
197:601-608[Medline].
|
| 23.
|
Hottiger, M. O., and G. J. Nabel.
1998.
Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein.
J. Virol.
72:8252-8256[Abstract/Free Full Text].
|
| 24.
|
Jones, K. A., and B. M. Peterlin.
1994.
Control of RNA initiation and elongation at the HIV-1 promoter.
Annu. Rev. Biochem.
63:717-743[Medline].
|
| 25.
|
Keaveney, M., and K. Struhl.
1998.
Activator-mediated recruitment of the RNA polymerase II machinery is the predominant mechanism for transcriptional activation in yeast.
Mol. Cell
1:917-924[Medline].
|
| 26.
|
Koleske, A. J., and R. A. Young.
1994.
An RNA polymerase II holoenzyme responsive to activators.
Nature
368:466-469[Medline].
|
| 27.
|
Lee, J. M., and A. L. Greenleaf.
1997.
Modulation of RNA polymerase II elongation efficiency by c-terminal heptapeptide repeat domain kinase I.
J. Biol. Chem.
272:10990-10993[Abstract/Free Full Text].
|
| 28.
|
Li, X.-Y., and M. R. Green.
1998.
The HIV-1 Tat cellular coactivator Tat-SF1 is a general transcription elongation factor.
Genes Dev.
12:2992-2996[Abstract/Free Full Text].
|
| 29.
|
Lu, X.,
T. M. Welsh, and B. M. Peterlin.
1993.
The human immunodeficiency virus type 1 long terminal repeat specifices two different transcription complexes, only one of which is regulated by Tat.
J. Virol.
67:1752-1760[Abstract/Free Full Text].
|
| 30.
|
Mack, D. H.,
J. Vartikar,
J. M. Pipas, and L. A. Laimins.
1993.
Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53.
Nature
363:281-283[Medline].
|
| 31.
|
Majello, B.,
G. Napolitano,
P. De Luca, and L. Lania.
1998.
Recruitment of human TBP selectively activates RNA polymerase II TATA-dependent promoters.
J. Biol. Chem.
273:16509-16516[Abstract/Free Full Text].
|
| 32.
|
Maldonado, E.,
R. Shiekhattar,
M. Sheldon,
H. Cho,
R. Drapkin,
P. Rickert,
E. Lees,
C. W. Anderson,
S. Linn, and D. Reinberg.
1996.
A human RNA polymerase II complex associated with SRB and DNA-repair proteins.
Nature
381:86-89[Medline].
|
| 33.
|
Malim, M. H.,
J. Hauber,
R. Fenrick, and B. R. Cullen.
1988.
Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes.
Nature
335:181-183[Medline].
|
| 34.
|
Mancebo, H.,
G. Lee,
J. Flygare,
J. Tomassini,
P. Luu,
Y. Zhu,
C. Blau,
D. Hazuda,
D. Price, and O. Flores.
1997.
P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro.
Genes Dev.
11:2633-2644[Abstract/Free Full Text].
|
| 35.
|
Marzio, G.,
M. Tyagi,
M. I. Gutierrez, and M. Giacca.
1998.
HIV-1 Tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter.
J. Biol. Chem.
95:13519-13524.
|
| 36.
|
Meulia, T.,
A. Krumm,
C. Spencer, and M. Groudine.
1992.
Sequences in the human c-myc P2 promoter affect the elongation and premature termination of transcripts initiated from the upstream P1 promoter.
Mol. Cell. Biol.
12:4590-4600[Abstract/Free Full Text].
|
| 37.
|
Mizushima, S., and S. Nagata.
1990.
pEF-BOS, a powerful mammalian expression vector.
Nucleic Acids Res.
18:5322[Free Full Text].
|
| 38.
|
Myer, V. E., and R. A. Young.
1998.
RNA polymerase II holoenzymes and subcomplexes.
J. Biol. Chem.
273:27757-27760[Free Full Text].
|
| 39.
|
Nakajima, T.,
C. Uchida,
S. F. Anderson,
J. D. Parvin, and M. Montminy.
1997.
Analysis of a cAMP-responsive activator reveals a two-component mechanism for transcriptional induction via signal-dependent factors.
Genes Dev.
11:738-747[Abstract/Free Full Text].
|
| 40.
|
Neish, A. S.,
S. F. Anderson,
B. P. Schlegel,
W. Wei, and J. D. Parvin.
1998.
Factors associated with the mammalian RNA polymerase II holoenzyme.
Nucleic Acids Res.
26:847-853[Abstract/Free Full Text].
|
| 41.
|
Neumann, J. R.,
C. A. Morency, and K. O. Russian.
1987.
A novel rapid assay for chloramphenicol acetyl transferase gene expression.
BioTechniques
5:444-447.
|
| 42.
|
Ohno, M., and Y. Shimura.
1996.
A human RNA helicase-like protein, HRH1, facilitates nuclear export of spliced mRNA by releasing the RNA from the spliceosome.
Genes Dev.
10:997-1007[Abstract/Free Full Text].
|
| 43.
|
Okamoto, H.,
C. T. Sheline,
J. L. Corden,
K. A. Jones, and B. M. Peterlin.
1996.
Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase II.
Proc. Natl. Acad. Sci. USA
93:11575-11579[Abstract/Free Full Text].
|
| 44.
|
Olsen, H. S., and C. A. Rosen.
1992.
Contribution of the TATA motif to Tat-mediated transcriptional activation of human immunodeficiency virus gene expression.
J. Virol.
66:5594-5597[Abstract/Free Full Text].
|
| 45.
|
Postigo, A. A.,
A. M. Sheppard,
M. L. Mucenski, and D. C. Dean.
1997.
c-Myb and Ets proteins synergize to overcome transcriptional repression by ZEB.
EMBO J.
16:3924-3934[Medline].
|
| 46.
|
Ranish, J. A.,
N. Yudkovsky, and S. Hahn.
1999.
Intermediates in formation and activity of the RNA polymerase II preinitiation complex: holoenzyme recruitment and a postrecruitment role for the TATA box and TFIIB.
Genes Dev.
13:49-63[Abstract/Free Full Text].
|
| 47.
|
Rosen, G. D.,
J. L. Barks,
M. F. Iademarco,
R. J. Fisher, and D. C. Dean.
1994.
An intricate arrangement of binding sites for the Ets family of transcription factors regulates activity of the integrin gene promoter.
J. Biol. Chem.
269:15652-15660[Abstract/Free Full Text].
|
| 48.
|
Rosen, G. D.,
J. R. Sanes,
R. LaChance,
J. M. Cunningham,
J. Roman, and D. C. Dean.
1992.
Roles for the integrin VLA-4 and its counter receptor VCAM-1 in myogenesis.
Cell
69:1107-1119[Medline].
|
| 49.
|
Song, C.-Z.,
P. M. Loewenstein, and M. Green.
1995.
Repression in vitro, by human adenovirus E1A protein domains, of basal or Tat-activated transcription of the human immunodeficiency virus type 1 long terminal repeat.
J. Virol.
69:2907-2911[Abstract].
|
| 50.
|
Suñé, C.,
R. Hayashi,
Y. Liu,
W. S. Lane,
R. A. Young, and M. A. Garcia-Blanco.
1997.
CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription.
Mol. Cell. Biol.
17:6029-6039[Abstract].
|
| 51.
|
Tansey, W. P.,
S. Ruppert,
R. Tjian, and W. Herr.
1994.
Multiple regions of TBP participate in the response to transcriptional activators in vivo.
Genes Dev.
8:2756-2769[Abstract/Free Full Text].
|
| 52.
|
Telesnitsky, A. P. W., and M. J. Chamberlin.
1996.
Sequences linked to prokaryotic promoters can affect the efficiency of downstream termination sites.
J. Mol. Biol.
205:315-330.
|
| 53.
|
Tsang, S. X.,
G. F. Morris,
M. Lu, and C. B. Morris.
1996.
TATA-dependent repression of human immunodeficiency virus type-1 transcription by the adenovirus E1A 243R oncoprotein.
Oncogene
12:819-826[Medline].
|
| 54.
|
Uptain, S. M.,
C. M. Kane, and M. J. Chamberlin.
1997.
Basic mechanisms of transcript elongation and its regulation.
Annu. Rev. Biochem.
66:117-172[Medline].
|
| 55.
|
Venot, C.,
M. Maratrat,
C. Dureuil,
E. Conseiller,
L. Bracco, and L. Debussche.
1998.
The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression.
EMBO J.
17:4668-4679[Medline].
|
| 56.
|
Ventura, A. M.,
M. Q. Arens,
A. Srinivasan, and G. Chinnadurai.
1990.
Silencing of human immunodeficiency virus long terminal repeat expression by an adenovirus E1a mutant.
Proc. Natl. Acad. Sci. USA
87:1310-1314[Abstract/Free Full Text].
|
| 57.
|
Wang, H. G. H.,
Y. Rikitake,
M. C. Carter,
P. Yaciuk,
S. E. Abraham,
B. Zerler, and E. Moran.
1993.
Identification of specific adenovirus E1A N-terminal residues critical to the binding of cellular proteins and to the control of cell growth.
J. Virol.
67:476-488[Abstract/Free Full Text].
|
| 58.
|
Wei, P.,
M. E. Garber,
S. Fang,
W. H. Fischer, and K. A. Jones.
1998.
A novel CDK9 associated c-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.
Cell
92:451-462[Medline].
|
| 59.
|
Xiao, H.,
J. T. Lis, and K. T. Jeang.
1997.
Promoter activity of Tat at steps subsequent to TATA-binding protein recruitment.
Mol. Cell. Biol.
17:6898-6905[Abstract].
|
| 60.
|
Yang, X.,
M. O. Gold,
D. N. Tang,
D. E. Lewis,
E. Aguilar-Cordova,
A. P. Rice, and C. H. Herrmann.
1997.
TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines.
Proc. Natl. Acad. Sci. USA
94:12331-12336[Abstract/Free Full Text].
|
| 61.
|
Yang, X.,
C. H. Herrmann, and A. P. Rice.
1996.
The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function.
J. Virol.
70:4576-4584[Abstract].
|
| 62.
|
Zawel, L., and D. Reinberg.
1995.
Common themes in assembly and function of eukaryotic transcription complexes.
Annu. Rev. Biochem.
64:533-561[Medline].
|
| 63.
|
Zenzie-Gregory, B.,
P. Sheridan,
K. A. Jones, and S. T. Smale.
1993.
HIV-1 core promoter lacks a simple initiator element but contains a bipartite activator at the transcription start site.
J. Biol. Chem.
268:15823-15832[Abstract/Free Full Text].
|
| 64.
|
Zhou, Q.,
D. Chen,
E. Pierstorff, and K. Luo.
1998.
Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages.
EMBO J.
17:3681-3691[Medline].
|
| 65.
|
Zhou, Q., and P. A. Sharp.
1996.
Tat-SF1: cofactor for stimulation of transcription elongation by HIV-1 Tat.
Science
274:605-610[Abstract/Free Full Text].
|
| 66.
|
Zhu, Y.,
T. Pe'ery,
J. Peng,
Y. Ramanathan,
N. Marshall,
T. Marshall,
B. Amendt,
M. Mathews, and D. Price.
1997.
Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro.
Genes Dev.
11:2622-2632[Abstract/Free Full Text].
|
Molecular and Cellular Biology, July 1999, p. 4719-4728, Vol. 19, No. 7
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Pearson, J. L., Robinson, T. J., Munoz, M. J., Kornblihtt, A. R., Garcia-Blanco, M. A.
(2008). Identification of the Cellular Targets of the Transcription Factor TCERG1 Reveals a Prevalent Role in mRNA Processing. J. Biol. Chem.
283: 7949-7961
[Abstract]
[Full Text]
-
Montanuy, I., Torremocha, R., Hernandez-Munain, C., Sune, C.
(2008). Promoter Influences Transcription Elongation: TATA-BOX ELEMENT MEDIATES THE ASSEMBLY OF PROCESSIVE TRANSCRIPTION COMPLEXES RESPONSIVE TO CYCLIN-DEPENDENT KINASE 9. J. Biol. Chem.
283: 7368-7378
[Abstract]
[Full Text]
-
Sanchez-Alvarez, M., Goldstrohm, A. C., Garcia-Blanco, M. A., Sune, C.
(2006). Human Transcription Elongation Factor CA150 Localizes to Splicing Factor-Rich Nuclear Speckles and Assembles Transcription and Splicing Components into Complexes through Its Amino and Carboxyl Regions.. Mol. Cell. Biol.
26: 4998-5014
[Abstract]
[Full Text]
-
McFie, P. J., Wang, G.-L., Timchenko, N. A., Wilson, H. L., Hu, X., Roesler, W. J.
(2006). Identification of a Co-repressor That Inhibits the Transcriptional and Growth-Arrest Activities of CCAAT/Enhancer-binding Protein {alpha}. J. Biol. Chem.
281: 18069-18080
[Abstract]
[Full Text]
-
Arango, M., Holbert, S., Zala, D., Brouillet, E., Pearson, J., Regulier, E., Thakur, A. K., Aebischer, P., Wetzel, R., Deglon, N., Neri, C.
(2006). CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant huntingtin neurotoxicity.. J. Neurosci.
26: 4649-4659
[Abstract]
[Full Text]
-
Smith, M. J., Kulkarni, S., Pawson, T.
(2004). FF Domains of CA150 Bind Transcription and Splicing Factors through Multiple Weak Interactions. Mol. Cell. Biol.
24: 9274-9285
[Abstract]
[Full Text]
-
Lin, K.-T., Lu, R.-M., Tarn, W.-Y.
(2004). The WW Domain-Containing Proteins Interact with the Early Spliceosome and Participate in Pre-mRNA Splicing In Vivo. Mol. Cell. Biol.
24: 9176-9185
[Abstract]
[Full Text]
-
Robson-Dixon, N. D., Garcia-Blanco, M. A.
(2004). MAZ Elements Alter Transcription Elongation and Silencing of the Fibroblast Growth Factor Receptor 2 Exon IIIb. J. Biol. Chem.
279: 29075-29084
[Abstract]
[Full Text]
-
Lund, L. H., Wahren, B., Garcia-Blanco, M. A.
(2003). A functional genetic approach suggests a novel interaction between the human immunodeficiency virus type 1 (HIV-1) Tat protein and HIV-1 TAR RNA in vivo. J. Gen. Virol.
84: 603-606
[Abstract]
[Full Text]
-
Carty, S. M., Greenleaf, A. L.
(2002). Hyperphosphorylated C-terminal Repeat Domain-associating Proteins in the Nuclear Proteome Link Transcription to DNA/Chromatin Modification and RNA Processing. Mol. Cell. Proteomics
1: 598-610
[Abstract]
[Full Text]
-
Goldstrohm, A. C., Albrecht, T. R., Sune, C., Bedford, M. T., Garcia-Blanco, M. A.
(2001). The Transcription Elongation Factor CA150 Interacts with RNA Polymerase II and the Pre-mRNA Splicing Factor SF1. Mol. Cell. Biol.
21: 7617-7628
[Abstract]
[Full Text]
-
Hermann, S., Berndt, K. D., Wright, A. P.
(2001). How Transcriptional Activators Bind Target Proteins. J. Biol. Chem.
276: 40127-40132
[Abstract]
[Full Text]
-
Holbert, S., Denghien, I., Kiechle, T., Rosenblatt, A., Wellington, C., Hayden, M. R., Margolis, R. L., Ross, C. A., Dausset, J., Ferrante, R. J., Neri, C.
(2001). The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: Neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proc. Natl. Acad. Sci. USA
98: 1811-1816
[Abstract]
[Full Text]
-
Carty, S. M., Goldstrohm, A. C., Sune, C., Garcia-Blanco, M. A., Greenleaf, A. L.
(2000). Protein-interaction modules that organize nuclear function: FF domains of CA150 bind the phosphoCTD of RNA polymerase II. Proc. Natl. Acad. Sci. USA
97: 9015-9020
[Abstract]
[Full Text]